Live bacterial cells as orally delivered therapeutics

2005 ◽  
Vol 5 (10) ◽  
pp. 1281-1301 ◽  
Author(s):  
Satya Prakash ◽  
Jasmine Bhathena
2020 ◽  
Vol 44 (46) ◽  
pp. 20334-20340
Author(s):  
Han Gao ◽  
Ying Ge ◽  
Min-Hao Jiang ◽  
Cheng Chen ◽  
Le-Yun Sun ◽  
...  

Antibiotic resistance mediated by β-lactamases including metallo-β-lactamases (MβLs) has become an emerging threat.


2010 ◽  
Vol 28 (No. 5) ◽  
pp. 392-406 ◽  
Author(s):  
D. Żyżelewicz ◽  
E. Nebesny ◽  
I. Motyl ◽  
Z. Libudzisz

Manufacturing of novel foodstuffs supplemented with live probiotic bacteria has recently been intensively investigated. The supplementation of confectionery with probiotics is troublesome since some unit technological processes are conducted at high temperatures and the products are usually stored at ambient temperature. Our group has developed a method of the production of milk chocolate, sweetened with either sucrose or isomalt and aspartame, containing 32, 36, or 40 g/100 g fat, and supplemented with live cells of probiotic bacterial strains: Lactobacillus casei and paracasei. This new milk chocolate displayed the same sensory properties as the reference, probiotic-free chocolate. The number of live bacterial cells was maintained at the functional level of 10<sup>6</sup> &divide; 10<sup>8</sup> cfu/g after keeping for 12 months irrespective of the temperature. The highest number of live probiotic bacteria survived in the chocolate kept at 4&deg;C. Thus the product can be regarded as functional food.


Author(s):  
Julie S. Biteen ◽  
Michael A. Thompson ◽  
Nicole K. Tselentis ◽  
Lucy Shapiro ◽  
W. E. Moerner

2013 ◽  
Vol 104 (2) ◽  
pp. 348a
Author(s):  
Robert Renthal ◽  
Abhinaya Govindaraj ◽  
Nayanish D. Lokhande ◽  
Daniel Gonzalez ◽  
Aaron Cassill

Vaccines ◽  
2020 ◽  
Vol 8 (2) ◽  
pp. 188 ◽  
Author(s):  
Esther Prados de la Torre ◽  
Antonio Rodríguez-Franco ◽  
Manuel J. Rodríguez-Ortega

Streptococcus suis is a Gram-positive bacterium responsible for major infections in pigs and economic losses in the livestock industry, but also an emerging zoonotic pathogen causing serious diseases in humans. No vaccine is available so far against this microorganism. Conserved surface proteins are among the most promising candidates for new and effective vaccines. Until now, research on this pathogen has focused on swine isolates, but there is a lack of studies to identify and characterize surface proteins from human clinical isolates. In this work, we performed a comparative proteomic analysis of six clinical isolates from human patients, all belonging to the major serotype 2, by “shaving” the live bacterial cells with trypsin, followed by LC-MS/MS analysis. We identified 131 predicted surface proteins and carried out a label-free semi-quantitative analysis of protein abundances within the six strains. Then, we combined our proteomics results with bioinformatic tools to help improving the selection of novel antigens that can enter the pipeline of vaccine candidate testing. Our work is then a complement to the reverse vaccinology concept.


Sign in / Sign up

Export Citation Format

Share Document